Latest News
See all →
ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026
Garching / Munich, February 25, 2026 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that…
Read more
ITM to Present at the 44th Annual J.P. Morgan Healthcare Conference
Garching / Munich, Germany, November 11, 2025 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today…
Read more
ITM Receives U.S. FDA Fast Track Designation for ITM-94 as a Diagnostic Agent for Clear Cell Renal Cell Carcinoma
- ITM-94 forms a theranostic pair with therapeutic candidate ITM-91, targeting carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma
Garching…
Read more
